Substantial Declines in eGFR After Initiation of SGLT2-Inhibitors Associate with Increased Short-term Mortality in Hospitalized Patients With CKD

Clicks: 8
ID: 337783
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #219 of 228 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 228 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are recommended as first-line therapy for patients with chronic kidney disease (CKD). However, the prevalence and prognostic significance of a large early eGFR dip after SGLT2i initiation in real-world CKD populations remain unclear. Methods We conducted a multicenter retrospective cohort study using the China Renal Data System. Adult hospitalized patients with estimated glomerular filtration rate (eGFR) ≥20 ml/min/1.73m2 who newly initiated SGLT2i were included. Exposure was defined as an eGFR decline ≥ 20% within 14–30 days after treatment initiation. Follow-up began 30 days after initiation. The outcomes were all-cause mortality within 45 days and all-cause mortality from 46 days to 1 year. Inverse probability of treatment weighting (IPTW)-weighted landmark Cox model was performed to evaluate these associations. Results Among 1 258 eligible patients (mean age 64.4 years; 69.3% male), 22.5% experienced an early eGFR dip ≥ 20%. Higher incidence rates were observed in older patients, those with heart failure, diuretic use, and CKD stages 2–4. Compared with an eGFR dip < 20%, an eGFR dip ≥ 20% was associated with an increased risk of all-cause mortality within 45 days (adjusted hazard ratio [aHR], 8.08; 95% confidence interval [CI], 3.41–19.13). However, no significant association was observed between an eGFR dip ≥ 20% and all-cause mortality from 46 days to 1 year (aHR, 0.91; 95% CI, 0.48–1.74). Conclusions A substantial eGFR decline after SGLT2i initiation was not uncommon and was associated with increased short-term all-cause mortality, highlighting the importance of close kidney function monitoring and individualized clinical assessment of treatment continuation.
Reference Key
openalex_W7224368940 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Qi Gao, Zhou Ma, Weirong Ren, Yaping Yu, Lunlun Wu, Zhiqin Zhang, Zhongcai Wu, Shiyu Zhou, Licong Su, Yanqin Li, Fan Luo, Yuxin Lin, Junwu Dong, Honglan Wei
Are you one of these authors? Claim your profile
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag386
URL
https://doi.org/10.1093/ckj/sfag386
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.